Suven Pharms's Generic Chloroquine Phosphate Receives Approval in the US
The European Medicines Agency’s safety committee (PRAC) has recommended updating the product information…
The U.S. Food and Drug Administration (FDA) warns the public about significant risks of chloroquine as the country received a hefty donation of pills from Bayer AG.
This is further to our letter dated 21st March, 2020 informing you about USFDA exemption from import alert for APls Chloroquine Phosphate and Hydroxycholoroquine Sulfate manufactured from Company's APls manufacturing facility situated at Ratlam (M.P)
FDA recently revoked a multi-month Emergency Use Authorization (the EUA) for use of chloroquine and hydroxychloroquine as an experimental treatment for patients suffering from COVID-19. FDA explained in its revocation letter that based on an analysis of months of data, it was determined that the drugs may not be effective to treat COVID-19, and, in fact, the known and potential risks outweighed the drugs’ potential benefits. This revocation covers only the EUA and does not affect the FDA approval of chloroquine and hydroxychloroquine for other uses. Indeed, there are additional clinical trials that continue to evaluate the potential benefit of these drugs in treating or preventing COVID-19.
The US now has 66 million excess anti-malaria pills after th .
Ipca Laboratories has remained a favourite of investors looking at export opportunities for chloroquine and hydroxychloroquine indicated in Covid-19 treatment. The stock that had gained 28.5 per cent since March lows, however, closed marginally lower on Tuesday as the company’s March quarter net profits came lower than expectations.
Hours after revoking its emergency use authorization (EUA) for hydroxychloroquine and chloroquine to treat coronavirus disease (COVID-19), the US Food and Drug Administration (FDA) is now warning that the drugs could interact with Gilead Sciences’ remdesivir, potentially reducing its antiviral activity.
The US Food and Drug Administration (FDA) has revoked the emergency use authorisation (EUA) for antimalarials, chloroquine phosphate and hydroxychloroquine sulfate, to treat some hospitalised Covid-19 patients.